"Boston Scientific continues to deliver industry-leading technologies that enhance patient quality of life," said David Pierce president of the Endoscopy business at Boston Scientific. "We are hopeful that the results of this study will demonstrate clinical benefit and cost effectiveness of a single metal stent approach versus plastic stenting, which typically requires multiple procedures."
The WallFlex Biliary RX Fully Covered Stent has a silicone polymer Permalume® Coating designed to reduce the potential for tumor/tissue ingrowth, and an integrated retrieval loop for removing or repositioning the stent in the event of incorrect placement during the initial procedure or for removal from benign strictures up to one year after placement. The stent is constructed of braided, platinum-cored Nitinol wire (Platinol™ Wire) and features three key components: radial force to help maintain duct patency and resist migration, flexibility to aid in conforming to tortuous anatomies and full-length radiopacity to enhance stent visibility under fluoroscopy.
The complete line of WallFlex Stents − Fully Covered, Partially Covered and Uncovered − is available in the United States and has CE Mark approval for use in the palliative treatment of malignant biliary strictures. In addition, the WallFlex Biliary RX Fully Covered stent is CE marked for the treatment of benign biliary strictures. The WallFlex Stent is the most frequently implanted biliary metal stent worldwide.
The WallFlex Stent is not approved in the United States for use in the treatment of benign biliary strictures. The safety and effectiveness of the stent for use in the vascular system have not been established.For more information, visit Boston Scientific Endoscopy Resources on-line at www.bostonscientific.com/endo-resources.
About Boston Scientific Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials and the importance of their findings, clinical outcomes, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.